Donanemab has already received a 'breakthrough therapy' designation from the FDA

Odds ratios for adverse mental health symptoms, especially suicidal ideation, highest for those in both roles

Incidence of dementia increased at age 66 and 80 years for those with schizophrenia versus those without serious mental illness

Decrease in life expectancy larger than that seen in other high-income countries; pronounced decreases seen for Hispanic, non-Hispanic Black populations